Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jalz.2007.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients.
Rev Alerg Mex
December 2024
Master's in economics, HS Pharmacoeconomic Research, Mexico City, Mexico.
Article Synopsis
- The study aimed to analyze the cost-effectiveness of budesonide/formoterol compared to other asthma treatments at Mexico's National Institute for Respiratory Diseases.
- Budesonide/formoterol had a lower average cost per patient ($733.36 USD) compared to fluticasone/vilanterol ($767.24 USD), and it showed a significant reduction in exacerbations with an incremental cost-effectiveness ratio (ICER) of $613.31 USD for better management.
- Overall, budesonide/formoterol was found to be a very cost-effective treatment option, suggesting it could reduce healthcare costs associated with emergency visits and hospitalizations despite fewer exacerbations per patient.
Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.
Pharmacoeconomics
January 2025
Division of Pulmonology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan, 704, Taiwan.
Background And Objective: Approximately half of lung adenocarcinomas in East Asia harbor epidermal growth factor receptor (EGFR) mutations. EGFR testing followed by tissue-based next-generation sequencing (NGS), upfront tissue-based NGS, and complementary NGS approaches have emerged on the front line to guide personalized therapy. We study the cost effectiveness of exclusionary EGFR testing for Taiwanese patients newly diagnosed with advanced lung adenocarcinoma.
View Article and Find Full Text PDFCross‑Cultural Validation of the Chronic Rhinosinusitis Patient-Reported Outcomes (CRS-PRO) Questionnaire in Portuguese.
Cureus
November 2024
Rhinology and Anterior Skull Base Surgery, University of Western Ontario, Ontario, CAN.
Introduction Chronic rhinosinusitis (CRS) presents with different clinical patterns with variable responses to treatment. Clear criteria for specifying disease severity and assessing symptom control are lacking in the current literature. We aimed to perform a cross-cultural adaptation of the chronic rhinosinusitis patient-reported outcomes (CRS-PRO), creating a Portuguese version to use as a routine questionnaire in the evaluation of patients with CRS.
View Article and Find Full Text PDFFenfluramine treatment for Dravet syndrome: Long term real-world analysis demonstrates safety and reduced health care burden.
Epilepsia
December 2024
Department of Neuroscience and Medical Genetics, Children's Hospital Meyer IRCCS, Florence, Italy.
Objective: Fenfluramine (FFA), stiripentol (STP), and cannabidiol (CBD) are approved add-on therapies for seizures in Dravet syndrome (DS). We report on the long-term safety and health care resource utilization (HCRU) of patients with DS treated with FFA under an expanded access program (EAP).
Methods: A cohort of 124 patients received FFA for a median of 2.
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.
Pharmacoeconomics
December 2024
Schumpeter School of Business and Economics, University of Wuppertal, Wuppertal, Germany.
Objectives: For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!